PanTher Therapeutics

PanTher Therapeutics Receives Ethics Approval to Initiate Phase 1 Clinical Trial of PTM-101 in Australia; Announces Appointment of Chief Medical Officer; Establishes Clinical Advisory Board

PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer